EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system

Anthony P Davenport iD, Majid Anwar, Rhoda E Kuc iD, Lena Brynne iD, Anne-Kristina Mercier iD, Magnus Åstrand iD, Peter J Greasley iD, Philip Ambery iD, Janet J Maguire iD

Canadian Journal of Physiology and Pharmacology · 01.01.2026 · 104 · 1-16

DOI: 10.1139/cjpp-2026-0068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.01.2026. Verfasst von Anthony P Davenport und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. Hauptthemen laut MEDLINE: Endothelins, Endothelin Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Astra Zeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelin–1 (ET–1) was discovered in 1988, followed by identification of ET A and ET B receptors in 1990, enabling rapid development of the first endothelin receptor antagonists (bosentan, ambrisentan, and macitentan) for pulmonary arterial hypertension, a condition marked by elevated ET–1. Nearly a decade later, a new therapeutic wave began with the ET B agonist sovateltide (2021) for cerebral ischemic stroke, demonstrating the benefits of ET B activation. More recent antagonist development has shifted toward ET A –selective agents to preserve ET B function. Clazosentan (ET A ) for cerebral vasospasm and aprocitentan (ET A /ET B ) for resistant hypertension extended endothelin–targeted therapy into more common diseases. In kidney disease, sparsentan (AT 1 /ET A ) and atrasentan (ET A ) have both been approved for IgA nephropathy, with atrasentan succeeding after earlier failed trials. Repurposing has become a major strategy in G protein–coupled receptor drug development. This review outlines approaches for identifying legacy endothelin compounds suitable for new indications, using zibotentan, now combined with dapagliflozin to reduce fluid retention as an example. Kidney disease remains a central focus of current trials, which include new ET A –selective diosuxentan and monoclonal antibody getagozumab, and the ET B peptide antagonist vodudeutentan. The review summarizes recent pharmacology and clinical data and highlights emerging strategies for next–generation endothelin–pathway therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndothelinsEndothelin Receptor AntagonistsHumansAnimalsReceptors, Endothelin

Stichwörter der Autor:innen

ETAETBendothelin-1sodium-glucose cotransporter-2sparsentanzibotentan

Substanzen

EndothelinsEndothelin Receptor AntagonistsReceptors, Endothelin

Autor:innen und Institutionen

  • Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Department of Cardiology, Royal Papworth Hospital, Cambridge, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Anthony P Davenport, Rhoda E Kuc, Lena Brynne, Anne-Kristina Mercier, Magnus Åstrand, Peter J Greasley, Philip Ambery, Janet J Maguire

Förderung

  • Wellcome Trust
  • Astra Zeneca

Zitieren

APA

Davenport, A., Anwar, M., Kuc, R., Brynne, L., Mercier, A., Åstrand, M., Greasley, P., Ambery, P., & Maguire, J. (2026). Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system. Canadian Journal of Physiology and Pharmacology, 104, 1-16. https://doi.org/10.1139/cjpp-2026-0068

Vancouver

Davenport A, Anwar M, Kuc R, Brynne L, Mercier A, Åstrand M, et al. Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system. Canadian Journal of Physiology and Pharmacology. 2026;104:1-16. doi:10.1139/cjpp-2026-0068

BibTeX
@article{Davenport2026,
  author = {Davenport, Anthony P and Anwar, Majid and Kuc, Rhoda E and Brynne, Lena and Mercier, Anne-Kristina and Åstrand, Magnus and Greasley, Peter J and Ambery, Philip and Maguire, Janet J},
  title = {Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2026},
  volume = {104},
  pages = {1--16},
  doi = {10.1139/cjpp-2026-0068}
}
Kostenlos starten →